CELEX: 32014L0003
Language: en
Date: 2013-10-18 00:00:00
Title: Commission Delegated Directive 2014/3/EU of 18 October 2013 amending, for the purposes of adapting to technical progress, the Annex IV to Directive 2011/65/EU of the European Parliament and of the Council as regards an exemption for lead acetate marker for use in stereotactic head frames for use with CT (Computed Tomography) and MRI and in positioning systems for gamma beam and particle therapy equipment  Text with EEA relevance

9.1.2014   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               L 4/49
            
         COMMISSION DELEGATED DIRECTIVE 2014/3/EU
   of 18 October 2013
   amending, for the purposes of adapting to technical progress, the Annex IV to Directive 2011/65/EU of the European Parliament and of the Council as regards an exemption for lead acetate marker for use in stereotactic head frames for use with CT (Computed Tomography) and MRI and in positioning systems for gamma beam and particle therapy equipment
   (Text with EEA relevance)
   THE EUROPEAN COMMISSION,
   Having regard to the Treaty on the Functioning of the European Union,
   Having regard to Directive 2011/65/EU of the European Parliament and of the Council of 8 June 2011 on the restriction of the use of certain hazardous substances in electrical and electronic equipment (1), and in particular Article 5(1)(a) thereof,
   Whereas:
   
               (1)
            
            
               Directive 2011/65/EU prohibits the use of lead in electrical and electronic equipment placed on the market.
            
         
               (2)
            
            
               Lead acetate is an ideal substance for use as marker within head-frames used for positioning for radiotherapy and gamma-ray tumour extractions procedures.
            
         
               (3)
            
            
               It is scientifically and technically impracticable to substitute or eliminate lead in the respective application and it appears that a practicable substitute will not become available in the near future.
            
         
               (4)
            
            
               Directive 2011/65/EU should therefore be amended accordingly,
            
         HAS ADOPTED THIS DIRECTIVE:
   Article 1
   Annex IV to Directive 2011/65/EU is amended as set out in the Annex to this Directive.
   Article 2
   1.   Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by the last day of the sixth month after entry into force at the latest. They shall forthwith communicate to the Commission the text of those provisions.
   When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.
   2.   Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.
   Article 3
   This Directive shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
   Article 4
   This Directive is addressed to the Member States.
   
      Done at Brussels, 18 October 2013.
      
         
            For the Commission
         
         
            The President
         
         José Manuel BARROSO
      
   
   
      (1)  OJ L 174, 1.7.2011, p. 88.
   
      ANNEX
      In Annex IV to Directive 2011/65/EU the following point 22 is added:
      
                  ‘22.
               
               
                  Lead acetate marker for use in stereotactic head frames for use with CT and MRI and in positioning systems for gamma beam and particle therapy equipment. Expires on 30 June 2021.’